Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: Overlaps in Down's syndrome and Alzheimer's disease brain

Biochemical Journal

Volumn 463, Issue 2, 2014, Pages 177-189

  Butterfield, D Allan ^a,b   Di Domenico, Fabio ^c   Swomley, Aaron M ^a   Head, Elizabeth ^a,b   Perluigi, Marzia ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Down's syndrome; Energy metabolism; Protein oxidation; Proteostasis network; Redox proteomics; Trisomy 21

Indexed keywords

CHAPERONE; SUPEROXIDE;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; AUTOPHAGY; BRAIN DYSFUNCTION; BRAIN FUNCTION; DOWN SYNDROME; GLUCOSE METABOLISM; HUMAN; METABOLIC DISORDER; MITOCHONDRIAL PERMEABILITY; NERVE DEGENERATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEOMICS; UPREGULATION; WESTERN BLOTTING; ANIMAL; BRAIN; GENETICS; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DOWN SYNDROME; HUMANS; NERVE DEGENERATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEOMICS;

EID: 84907196714     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20140772     Document Type: Article

References (138)

1. Uttara, B., and Singh., A. V., Zamboni, P. and Mahajan, R. T. (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7, 65-74
2. Halliwell, B. (1991) Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am. J. Med. 91, 14S-22S
3. 2formation by rat heart mitochondria on substrate availability and donor age. J. Bioenerg. Biomembr. 29, 89-95
4. Lenaz, G. (2001) The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMB Life 52, 159-164
5. Ray, P. D., Huang, B. W. and Tsuji, Y. (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell. Signal. 24, 981-990
6. Finkel, T. and Holbrook, N. J. (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408, 239-247
7. Lambeth, J. D. (2004) NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4, 181-189
8. Sies, H. (1993) Strategies of antioxidant defense. Eur. J. Biochem. 215, 213-219
9. Droge, W. (2002) Free radicals in the physiological control of cell function. Physiol. Rev. 82, 47-95
10. Halliwell, B. (2006) Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97, 1634-1658
11. Perluigi, M., Swomley, A. M. and Butterfield, D. A. (2014) Redox proteomics and the dynamic molecular landscape of the aging brain. Ageing Res. Rev. 13, 75-89
12. Butterfield, D. A., Perluigi, M., Reed, T., Muharib, T., and Hughes., C. P., Robinson, R. A. and Sultana, R. (2012) Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid. Redox Signal. 17, 1610-1655
13. Malkus, K. A., Tsika, E. and Ischiropoulos, H. (2009) Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol. Neurodegener. 4, 24
14. Grune, T., Merker, K., Jung, T., Sitte, N. and Davies, K. J. (2005) Protein oxidation and degradation during postmitotic senescence. Free Radic. Biol. Med. 39, 1208-1215
15. Metcalf, D. J., Garcia-Arencibia, M., Hochfeld, W. E. and Rubinsztein, D. C. (2012) Autophagy and misfolded proteins in neurodegeneration. Exp. Neurol. 238, 22-28
16. Yang, Z. and Klionsky, D. J. (2010) Mammalian autophagy: core molecular machinery and signaling regulation. Curr. Opin. Cell Biol. 22, 124-131
17. Nixon, R. A. (2013) The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983-997
18. Keller, J. N., Dimayuga, E., Chen, Q., Thorpe, J., Gee, J. and Ding, Q. (2004) Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. Int. J. Biochem. Cell Biol. 36, 2376-2391
19. Grune, T., Reinheckel, T., Joshi, M. and Davies, K. J. (1995) Proteolysis in cultured liver epithelial cells during oxidative stress. Role of the multicatalytic proteinase complex, proteasome. J. Biol. Chem. 270, 2344-2351
20. Friguet, B. and Szweda, L. I. (1997) Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein. FEBS Lett. 405, 21-25
21. Lin, M. T. and Beal, M. F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795
22. Liu, C. W., Li, X., Thompson, D., Wooding, K., and Chang., T. L., Tang, Z., Yu, H., Thomas, P. J. and DeMartino, G. N. (2006) ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Mol. Cell 24, 39-50
23. Mijaljica, D., Prescott, M. and Devenish, R. J. (2011) V-ATPase engagement in autophagic processes. Autophagy 7, 666-668
24. Hohn, A., Konig, J. and Grune, T. (2013) Protein oxidation in aging and the removal of oxidized proteins. J. Proteomics 92, 132-159
25. Agarwal, S. and Sohal, R. S. (1996) Relationship between susceptibility to protein oxidation, aging, and maximum life span potential of different species. Exp. Gerontol. 31, 365-372
26. Harman, D. (1956) Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 11, 298-300
27. Yang, H. Y., and Chay., K. O., Kwon, J., Kwon, S. O., Park, Y. K. and Lee, T. H. (2013) Comparative proteomic analysis of cysteine oxidation in colorectal cancer patients. Mol. Cells 35, 533-542
28. Ma, Y., Zhang, L., Rong, S., Qu, H., Zhang, Y., Chang, D., Pan, H. and Wang, W. (2013) Relation between gastric cancer and protein oxidation, DNA damage, and lipid peroxidation. Oxid. Med. Cell Longev. 2013, 543760
29. Reed, T. T., and Pierce., W. M., Markesbery, W. R. and Butterfield, D. A. (2009) Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res. 1274, 66-76
30. Aksenov, M. Y., and Aksenova., M. V., Butterfield, D. A., Geddes, J. W. and Markesbery, W. R. (2001) Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103, 373-383
31. Di Domenico, F., Coccia, R., Butterfield, D. A. and Perluigi, M. (2011) Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits. Biochim. Biophys. Acta 1814, 1785-1795
32. Dean, R. T., Fu, S., Stocker, R. and Davies, M. J. (1997) Biochemistry and pathology of radical-mediated protein oxidation. Biochem. J. 324, 1-18
33. Dunlop, R. A., Brunk, U. T. and Rodgers, K. J. (2009) Oxidized proteins: mechanisms of removal and consequences of accumulation. IUBMB Life 61, 522-527
34. Butterfield, D. A., Reed, T., Perluigi, M., De Marco, C., Coccia, R., Cini, C. and Sultana, R. (2006) Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci. Lett. 397, 170-173
35. Markesbery, W. R. and Lovell, M. A. (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 19, 33-36
36. Weidner, A. M., and Bradley., M. A., Beckett, T. L., Niedowicz, D. M., and Dowling., A. L., Matveev, S. V., LeVine, 3rd, H., Lovell, M. A. and Murphy, M. P. (2011) RNA oxidation adducts 8-OHG and 8-OHA change with Aβ42 levels in late-stage Alzheimer's disease. PLoS One 6, e24930
37. Markesbery, W. R. and Lovell, M. A. (2006) DNA oxidation in Alzheimer's disease. Antioxid. Redox Signal. 8, 2039-2045
38. Perluigi, M., Di Domenico, F., Giorgi, A., Schinina, M. E., Coccia, R., Cini, C., Bellia, F., Cambria, M. T., Cornelius, C., Butterfield, D. A. and Calabrese, V. (2010) Redox proteomics in aging rat brain: involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process. J. Neurosci. Res. 88, 3498-3507
39. Cabiscol, E., Tamarit, J. and Ros, J. (2014) Protein carbonylation: proteomics, specificity and relevance to aging. Mass Spectrom. Rev. 33, 21-48
40. Suzuki, Y. J., Carini, M. and Butterfield, D. A. (2010) Protein carbonylation. Antioxid. Redox Signal. 12, 323-325
41. Butterfiled, D. A. and Stadtman, E. R. (1997) Protein oxidation processes in aging brain. Advances Cell Aging Gerontol. 2, 161-191
42. Stadtman, E. R. and Levine, R. L. (2000) Protein oxidation. Ann. N.Y. Acad. Sci. 899, 191-208
43. Wong, C. M., Marcocci, L., Liu, L. and Suzuki, Y. J. (2010) Cell signaling by protein carbonylation and decarbonylation. Antioxid. Redox Signal. 12, 393-404
44. Wong, C. M., Bansal, G., Marcocci, L. and Suzuki, Y. J. (2012) Proposed role of primary protein carbonylation in cell signaling. Redox Rep. 17, 90-94
45. Markesbery, W. R. (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134-147
46. Butterfield, D. A., Drake, J., Pocernich, C. and Castegna, A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide. Trends Mol. Med. 7, 548-554
47. Butterfield, D. A., Galvan, V., Lange, M. B., Tang, H., and Sowell., R. A., Spilman, P., Fombonne, J., Gorostiza, O., Zhang, J., Sultana, R. and Bredesen, D. E. (2010) In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid β-peptide of APP. Free Radic. Biol. Med. 48, 136-144
48. Butterfield, D. A. and Boyd-Kimball, D. (2005) The critical role of methionine 35 in Alzheimer's amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim. Biophys. Acta 1703, 149-156
49. Butterfield, D. A., Castegna, A., Lauderback, C. M. and Drake, J. (2002) Evidence that amyloid β-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol. Aging 23, 655-664
50. Shichiri, M. (2014) The role of lipid peroxidation in neurological disorders. J. Clin. Biochem. Nutr. 54, 151-160
51. Butterfield, D. A., Bader Lange, M. L. and Sultana, R. (2010) Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 1801, 924-929
52. Mark, R. J., and Lovell., M. A., Markesbery, W. R., Uchida, K. and Mattson, M. P. (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J. Neurochem. 68, 255-264
53. Lange, M. L. B., Cenini, G., Piroddi, M., Abdul, H. M., Sultana, R., Galli, F., Memo, M. and Butterfield, D. A. (2008) Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol. Dis. 29, 456-464
54. Yang, X., Wu, X., Choi, Y. E., Kern, J. C. and Kehrer, J. P. (2004) Effect of acrolein and glutathione depleting agents on thioredoxin. Toxicology 204, 209-218
55. Igarashi, K. and Kashiwagi, K. (2011) Protein-conjugated acrolein as a biochemical marker of brain infarction. Mol. Nutr. Food Res. 55, 1332-1341
56. Lee, W. C., and Wong., H. Y., Chai, Y. Y., Shi, C. W., Amino, N., Kikuchi, S. and Huang, S. H. (2012) Lipid peroxidation dysregulation in ischemic stroke: plasma 4-HNE as a potential biomarker? Biochem. Biophys. Res. Commun. 425, 842-847
57. Calabrese, V., Cornelius, C., Rizzarelli, E., Owen, J. B., Dinkova-Kostova, A. T. and Butterfield, D. A. (2009) Nitric oxide in cell survival: a janus molecule. Antioxid. Redox Signal. 11, 2717-2739
58. Nelson, E. J., Connolly, J. and McArthur, P. (2003) Nitric oxide and S-nitrosylation: excitotoxic and cell signaling mechanism. Biol. Cell 95, 3-8
59. Shahani, N. and Sawa, A. (2011) Nitric oxide signaling and nitrosative stress in neurons: role for S-nitrosylation. Antioxid. Redox Signal. 14, 1493-1504
60. Stamler, J. S. (1994) Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 78, 931-936
61. Ahsan, H. (2013) 3-Nitrotyrosine: a biomarker of nitrogen free radical species modified proteins in systemic autoimmunogenic conditions. Hum. Immunol. 74, 1392-1399
62. Barone, E., Di Domenico, F., Cenini, G., Sultana, R., Cini, C., Preziosi, P., Perluigi, M., Mancuso, C. and Butterfield, D. A. (2011) Biliverdin reductase: a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim. Biophys. Acta 1812, 480-487
63. Alvarez, B. and Radi, R. (2003) Peroxynitrite reactivity with amino acids and proteins. Amino Acids 25, 295-311
64. Foster, M. W., Hess, D. T. and Stamler, J. S. (2009) Protein S-nitrosylation in health and disease: a current perspective. Trends Mol. Med. 15, 391-404
65. Broniowska, K. A. and Hogg, N. (2012) The chemical biology of S-nitrosothiols. Antioxid. Redox Signal. 17, 969-980
66. Sultana, R. and Butterfield, D. A. (2013) Oxidative modification of brain proteins in Alzheimer's disease: perspective on future studies based on results of redox proteomics studies. J. Alzheimers Dis. 33, S243-S251
67. Perluigi, M., Di Domenico, F. and Buttterfield, D. A. (2014) Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics. Proteomics Clin. Appl. 8, 73-85
68. Mann, D. M., Brown, A., Wilks, D. P. and Davies, C. A. (1989) Immunocytochemical and lectin histochemical studies of plaques and tangles in Down's syndrome patients at different ages. Prog. Clin. Biol. Res. 317, 849-856
69. Wisniewski, H. M. and Rabe, A. (1986) Discrepancy between Alzheimer-type neuropathology and dementia in persons with Down's syndrome. Ann. N.Y. Acad. Sci. 477, 247-260
70. Lott, I. T. (2012) Neurological phenotypes for Down syndrome across the life span. Prog. Brain Res. 197, 101-121
71. Rueda, N., Florez, J. and Martinez-Cue, C. (2012) Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast. 2012, 584071
72. Gardiner, K. (2004) Gene-dosage effects in Down syndrome and trisomic mouse models. Genome Biol. 5, 244
73. Schupf, N. and Sergievsky, G. H. (2002) Genetic and host factors for dementia in Down's syndrome. Br. J. Psychiatry 180, 405-410
74. Perluigi, M. and Butterfield, D. A. (2012) Oxidative stress and down syndrome: a route toward Alzheimer-like dementia. Curr. Gerontol. Geriatr. Res. 2012, 724904
75. Spickett, C. M. (2013) The lipid peroxidation product 4-hydroxy-2-nonenal: advances in chemistry and analysis. Redox Biol. 1, 145-152
76. Gulesserian, T., Engidawork, E., Fountoulakis, M. and Lubec, G. (2001) Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome. J. Neural. Transm. Suppl. 71-84
77. Mehta, P. D., Capone, G., Jewell, A. and Freedland, R. L. (2007) Increased amyloid β protein levels in children and adolescents with Down syndrome. J. Neurol. Sci. 254, 22-27
78. Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H. and Yankner, B. A. (2002) Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33, 677-688
79. Head, E., Garzon-Rodriguez, W., Johnson, J. K., and Lott., I. T., Cotman, C. W. and Glabe, C. (2001) Oxidation of Aβ and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol. Dis. 8, 792-806
80. Nunomura, A., Perry, G., Pappolla, M. A., and Friedland., R. P., Hirai, K., Chiba, S. and Smith, M. A. (2000) Neuronal oxidative stress precedes amyloid-β deposition in Down syndrome. J. Neuropathol. Exp. Neurol. 59, 1011-1017
81. 2-isoprostanes, is not increased in Down syndrome. Ann. Epidemiol. 22, 892-894
82. Campos, C., Guzman, R., Lopez-Fernandez, E. and Casado, A. (2011) Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome. Biochim. Biophys. Acta 1812, 760-768
83. Perluigi, M., di Domenico, F., Fiorini, A., Cocciolo, A., Giorgi, A., Foppoli, C., Butterfield, D. A., Giorlandino, M., Giorlandino, C., Schinina, M. E. and Coccia, R. (2011) Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Proteomics Clin. Appl. 5, 167-178
84. Coskun, P. E., Wyrembak, J., Derbereva, O., Melkonian, G., Doran, E., Lott, I. T., Head, E., Cotman, C. W. and Wallace, D. C. (2010) Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J. Alzheimers Dis. 20 (Suppl. 2), S293-S310
85. Lott, I. T., Head, E., Doran, E. and Busciglio, J. (2006) β-Amyloid, oxidative stress and down syndrome. Curr. Alzheimer Res. 3, 521-528
86. Valenti, D., and Manente., G. A., Moro, L., Marra, E. and Vacca, R. A. (2011) Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway. Biochem. J. 435, 679-688
87. Arbuzova, S., Hutchin, T. and Cuckle, H. (2002) Mitochondrial dysfunction and Down's syndrome. BioEssays 24, 681-684
88. Helguera, P., Seiglie, J., Rodriguez, J., Hanna, M., Helguera, G. and Busciglio, J. (2013) Adaptive downregulation of mitochondrial function in down syndrome. Cell. Metab. 17, 132-140
89. Tabner, B. J., El-Agnaf, O. M., Turnbull, S., German, M. J., Paleologou, K. E., Hayashi, Y., Cooper, L. J., Fullwood, N. J. and Allsop, D. (2005) Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J. Biol. Chem. 280, 35789-35792
90. Chen, B., Retzlaff, M., Roos, T. and Frydman, J. (2011) Cellular strategies of protein quality control. Cold Spring Harb. Perspect. Biol. 3, a004374
91. Morawe, T., Hiebel, C., Kern, A. and Behl, C. (2012) Protein homeostasis, aging and Alzheimer's disease. Mol. Neurobiol. 46, 41-54
92. Blair, L. J., Zhang, B. and Dickey, C. A. (2013) Potential synergy between tau aggregation inhibitors and tau chaperone modulators. Alzheimers Res. Ther. 5, 41
93. van der Putten, H. and Lotz, G. P. (2013) Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases. Neurotherapeutics 10, 416-428
94. Di Domenico, F., Coccia, R., Cocciolo, A., Murphy, M. P., Cenini, G., Head, E., Butterfield, D. A., Giorgi, A., Schinina, M. E., Mancuso, C. et al. (2013) Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim. Biophys. Acta 1832, 1249-1259
95. Di Domenico, F., Pupo, G., Tramutola, A., Giorgi, A., Schinina, M. E., Coccia, R., Head, E., Butterfield, D. A. and Perluigi, M. (2014) Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radic. Biol. Med. 71, 270-280
96. Chakrabarti, A., Chen, A. W. and Varner, J. D. (2011) A review of the mammalian unfolded protein response. Biotechnol. Bioeng. 108, 2777-2793
97. Doyle, K. M., Kennedy, D., Gorman, A. M., Gupta, S., Healy, S. J. and Samali, A. (2011) Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J. Cell. Mol. Med. 15, 2025-2039
98. Kouchi, Z., Sorimachi, H., Suzuki, K. and Ishiura, S. (1999) Proteasome inhibitors induce the association of Alzheimer's amyloid precursor protein with Hsc73. Biochem. Biophys. Res. Commun. 254, 804-810
99. Vembar, S. S. and Brodsky, J. L. (2008) One step at a time: endoplasmic reticulum-associated degradation. Nat. Rev. Mol. Cell Biol. 9, 944-957
100. Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V., and Klein., J. B., Pierce, W. M., Booze, R., Markesbery, W. R. and Butterfield, D. A. (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33, 562-571
101. Butterfield, D. A., Boyd-Kimball, D. and Castegna, A. (2003) Proteomics in Alzheimer's disease: new insights into mechanisms of neurodegeneration. J. Neurochem. 86, 1313-1327
102. Choi, J., and Levey., A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L. S. and Li, L. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279, 13256-13264
103. Butterfield, D. A., Gnjec, A., Poon, H. F., Castegna, A., and Pierce., W. M., Klein, J. B. and Martins, R. N. (2006) Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J. Alzheimers Dis. 10, 391-397
104. Butterfield, D. A., and Reed., T. T., Perluigi, M., De Marco, C., Coccia, R., Keller, J. N., Markesbery, W. R. and Sultana, R. (2007) Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 1148, 243-248
105. Hegde, A. N. (2010) The ubiquitin-proteasome pathway and synaptic plasticity. Learn. Mem. 17, 314-327
106. Hochfeld, W. E., Lee, S. and Rubinsztein, D. C. (2013) Therapeutic induction of autophagy to modulate neurodegenerative disease progression. Acta Pharmacol. Sin. 34, 600-604
107. Bandyopadhyay, U., Sridhar, S., Kaushik, S., Kiffin, R. and Cuervo, A. M. (2010) Identification of regulators of chaperone-mediated autophagy. Mol. Cell 39, 535-547
108. Kiffin, R., Christian, C., Knecht, E. and Cuervo, A. M. (2004) Activation of chaperone-mediated autophagy during oxidative stress. Mol. Biol. Cell 15, 4829-4840
109. Boyd-Kimball, D., Castegna, A., Sultana, R., Poon, H. F., Petroze, R., and Lynn., B. C., Klein, J. B. and Butterfield, D. A. (2005) Proteomic identification of proteins oxidized by Aβ (1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res. 1044, 206-215
110. 2or 2, 2-azobis-(2-amidinopropane) dihydrochloride by the glutathione mimetic tricyclodecan-9-yl-xanthogenate. Free Radic. Biol. Med. 38, 1023-1031
111. de la Monte, S. M. (2012) Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 9, 35-66
112. de la Monte, S. M. (2012) Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 72, 49-66
113. Steen, E., and Terry., B. M., Rivera, E. J., Cannon, J. L., and Neely., T. R., Tavares, R., Xu, X. J., Wands, J. R. and de la Monte, S. M. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease: is this type 3 diabetes? J. Alzheimers Dis. 7, 63-80
114. Swomley, A. M., Forster, S., Keeney, J. T., Triplett, J., Zhang, Z., Sultana, R. and Butterfield, D. A. (2014) Aβ, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim. Biophys. Acta 1842, 1248-1257
115. Butterfield, D. A., Perluigi, M. and Sultana, R. (2006) Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur. J. Pharmacol. 545, 39-50
116. Butterfield, D. A., Swomley, A. M. and Sultana, R. (2013) Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal. 19, 823-835
117. de la Monte, S. M. and Tong, M. (2014) Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem. Pharmacol. 88, 548-559
118. Butterfield, D. A. (2006) Oxidative stress in neurodegenerative disorders. Antioxid. Redox Signal. 8, 1971-1973
119. Pratico, D. (2008) Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol. Sci. 29, 609-615
120. Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S. et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 759-767
121. Planel, E., Miyasaka, T., Launey, T., Chui, D. H., Tanemura, K., Sato, S., Murayama, O., Ishiguro, K., Tatebayashi, Y. and Takashima, A. (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J. Neurosci. 24, 2401-2411
122. Chen, Z. and Zhong, C. (2013) Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 108, 21-43
123. Coskun, P. E. and Busciglio, J. (2012) Oxidative stress and mitochondrial dysfunction in Down's syndrome: relevance to aging and dementia. Curr. Gerontol. Geriatr. Res. 2012, 383170
124. Butterfield, D. A. and Dalle-Donne, I. (2014) Redox proteomics: from protein modifications to cellular dysfunction and disease. Mass Spectrom. Rev. 33, 1-6
125. Aluise, C. D., and Robinson., R. A., Cai, J., Pierce, W. M., Markesbery, W. R. and Butterfield, D. A. (2011) Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. J. Alzheimers Dis. 23, 257-269
126. Butterfield, D. A. and Sultana, R. (2007) Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis. 12, 61-72
127. Sultana, R., and Poon., H. F., Cai, J., Pierce, W. M., Merchant, M., and Klein., J. B., Markesbery, W. R. and Butterfield, D. A. (2006) Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 22, 76-87
128. Sultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J., and Pierce., W. M., Klein, J. B., Merchant, M., Markesbery, W. R. and Butterfield, D. A. (2006) Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging. 27, 1564-1576
129. Hoyer, S. (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 490, 115-125
130. Ishihara, K., Amano, K., Takaki, E., Ebrahim, A. S., Shimohata, A., Shibazaki, N., Inoue, I., Takaki, M., Ueda, Y., Sago, H., Epstein, C. J. and Yamakawa, K. (2009) Increased lipid peroxidation in Down's syndrome mouse models. J. Neurochem. 110, 1965-1976
131. Martin, S. B., and Dowling., A. L., Lianekhammy, J., Lott, I. T., Doran, E., and Murphy., M. P., Beckett, T. L., Schmitt, F. A. and Head, E. (2014) Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease. J. Alzheimers Dis., 10.3233/JAD-140795
132. Vexler, Z. S., Wong, A., Francisco, C., Manabat, C., Christen, S., Tauber, M., Ferriero, D. M. and Gregory, G. (2003) Fructose-1, 6-bisphosphate preserves intracellular glutathione and protects cortical neurons against oxidative stress. Brain Res. 960, 90-98
133. Golej, J., Hoeger, H., Radner, W., Unfried, G. and Lubec, G. (1998) Oral administration of methylglyoxal leads to kidney collagen accumulation in the mouse. Life Sci. 63, 801-807
134. Butterfield, D. A., Hardas, S. S. and Lange, M. L. (2010) Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration. J. Alzheimers Dis. 20, 369-393
135. Butterfield, D. A. and Lange, M. L. (2009) Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J. Neurochem. 111, 915-933
136. Reed, T., Perluigi, M., Sultana, R., Pierce, W. M., and Klein., J. B., Turner, D. M., Coccia, R., Markesbery, W. R. and Butterfield, D. A. (2008) Redox proteomic identification of 4-Hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 30, 107-120
137. Lauderback, C. M., and Hackett., J. M., Huang, F. F., Keller, J. N., and Szweda., L. I., Markesbery, W. R. and Butterfield, D. A. (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Aβ 1-42. J. Neurochem. 78, 413-416
138. Butterfield, D. A., Gu, L., Domenico, F. D. and Robinson, R. A. (2014) Mass spectrometry and redox proteomics: applications in disease. Mass Spectrom. Rev. 33, 277-301